HealthlineFDA OKs Lipfendra, a Groundbreaking New Pill to Lower Cholesterol

📋 Regulatory Action / Label Change

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, providing an alternative to injectable agents in this class. Phase 3 studies demonstrated approximately 56%-59% LDL cholesterol reductions in statin-treated adults with hypercholesterolemia.

Clinical Considerations

• First oral PCSK9 inhibitor expands administration options beyond existing injectable therapies.
• LDL cholesterol fell approximately 56%-59% across pivotal studies involving more than 3,200 participants.
• Approval was based on LDL-C lowering rather than demonstrated reductions in cardiovascular events.
• Ongoing outcomes trials will determine whether LDL reductions translate into lower rates of myocardial infarction and stroke.

Practice Applications

• Consider oral PCSK9 inhibition for patients reluctant to use injections.
• Recognize enlicitide as an adjunct to maximally tolerated statin therapy.
• Interpret LDL reduction as a surrogate endpoint pending outcomes data.
• Monitor formulary access, cost, and insurance coverage considerations.